AnaptysBio, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2014 | — | $-30.8M | $22.3M |
| Dec 2015 | — | $-35.2M | $51.7M |
| Jun 2016 | — | — | $50.6M |
| Sep 2016 | — | — | $47.2M |
| Dec 2016 | — | $-38.2M | $51.2M |
| Mar 2017 | — | $110.1M | $96.8M |
| Jun 2017 | — | $109.2M | $30.8M |
| Sep 2017 | — | $101.4M | $26.7M |
| Dec 2017 | — | $307.6M | $81.2M |
| Mar 2018 | — | $294.5M | $69.5M |
| Jun 2018 | — | $285.0M | $57.1M |
| Sep 2018 | — | $499.7M | $293.4M |
| Dec 2018 | — | $486.4M | $113.6M |
| Mar 2019 | — | $468.2M | $105.9M |
| Jun 2019 | — | $448.4M | $146.6M |
| Sep 2019 | — | $420.9M | $182.9M |
| Dec 2019 | — | $405.0M | $171.0M |
| Mar 2020 | — | $400.6M | $165.3M |
| Jun 2020 | — | $381.4M | $221.2M |
| Sep 2020 | — | $360.2M | $209.2M |
| Dec 2020 | — | $396.7M | $250.5M |
| Mar 2021 | — | $381.9M | $284.1M |
| Jun 2021 | — | $385.7M | $332.3M |
| Sep 2021 | — | $383.6M | $336.3M |
| Dec 2021 | — | $356.4M | $495.7M |
| Mar 2022 | — | $330.7M | $166.4M |
| Jun 2022 | — | $304.3M | $71.7M |
| Sep 2022 | — | $277.6M | $58.5M |
| Dec 2022 | — | $262.1M | $71.3M |
| Mar 2023 | — | $191.1M | $94.6M |
| Jun 2023 | — | $148.5M | $35.2M |
| Sep 2023 | — | $120.4M | $26.3M |
| Dec 2023 | — | $88.1M | $36.0M |
| Mar 2024 | — | $47.8M | $53.7M |
| Jun 2024 | — | $9.9M | $71.8M |
| Sep 2024 | — | $84.4M | $191.6M |
| Dec 2024 | — | $70.9M | $23.1M |
| Mar 2025 | — | $34.0M | $98.6M |
| Jun 2025 | — | $-44.7M | $44.3M |
| Sep 2025 | — | $-29.4M | $109.8M |
| Dec 2025 | — | $37.2M | $138.2M |
| Mar 2026 | — | $12.7M | $248.5M |
| Jun 2026 | — | $10.6M | $133.8M |